Corvus Pharmaceuticals Inc (NASDAQ: CRVS) kicked off on Monday, down -9.24% from the previous trading day, before settling in for the closing price of $9.09. Over the past 52 weeks, CRVS has traded in a range of $1.30-$10.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -65.36%. With a float of $49.95 million, this company’s outstanding shares have now reached $62.58 million.
The firm has a total of 28 workers. Let’s measure their productivity. In terms of profitability, gross margin is 70.73%, operating margin of -10200.81%, and the pretax margin is -23102.85%.
Corvus Pharmaceuticals Inc (CRVS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Corvus Pharmaceuticals Inc is 22.27%, while institutional ownership is 28.59%. The most recent insider transaction that took place on May 06 ’24, was worth 34,624. In this transaction an insider of this company bought 20,000 shares at a rate of $1.73, taking the stock ownership to the 153,773 shares. Before that another transaction happened on May 06 ’24, when Company’s President and CEO bought 577,634 for $1.73, making the entire transaction worth $1,000,000. This insider now owns 577,634 shares in total.
Corvus Pharmaceuticals Inc (CRVS) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.14 earnings per share (EPS), lower than consensus estimate (set at -0.13) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -65.36% per share during the next fiscal year.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
Take a look at Corvus Pharmaceuticals Inc’s (CRVS) current performance indicators. Last quarter, stock had a quick ratio of 0.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.93, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
Analysing the last 5-days average volume posted by the [Corvus Pharmaceuticals Inc, CRVS], we can find that recorded value of 0.53 million was better than the volume posted last year of 0.38 million. As of the previous 9 days, the stock’s Stochastic %D was 60.11%. Additionally, its Average True Range was 0.71.
During the past 100 days, Corvus Pharmaceuticals Inc’s (CRVS) raw stochastic average was set at 78.23%, which indicates a significant increase from 21.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.69% in the past 14 days, which was lower than the 87.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.54, while its 200-day Moving Average is $3.76. Now, the first resistance to watch is $8.87. This is followed by the second major resistance level at $9.50. The third major resistance level sits at $9.83. If the price goes on to break the first support level at $7.91, it is likely to go to the next support level at $7.58. Should the price break the second support level, the third support level stands at $6.95.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Key Stats
The company with the Market Capitalisation of 511.55 million has total of 64,257K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -27,030 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -40,220 K.
